| Anticancer Fund

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?

Pantziarka, P., Bouche, G., & André, N. (2018). “Hard” Drug Repurposing for Precision Oncology: The Missing Link? Frontiers in Pharmacology; 9, 637. doi:10.3389/fphar.2018.00637

Thu, 06/14/2018 - 12:00

European Pancreatic Club Meeting 2018

13 – 16 June 2018 | Berlin, Germany

Wed, 06/13/2018 - 12:00

ASCO Annual Meeting 2018

1-5 June 2018 | McCormick Place, Chicago | #ASCO18

Mon, 06/04/2018 - 12:00

Drug Repurposing as a Source of Innovative Therapies in Osteosarcoma

presented during the Sarcoma Poster Session on ASCO18

Sat, 06/02/2018 - 12:00

Annual Impact Sheet 2017

Thu, 04/19/2018 - 12:00

ReDO: selective PDE5 inhibitors as anti-cancer agents

Pantziarka, P., Sukhatme, V., Crispino, S., Bouche, G., Meheus, L., & Sukhatme, V. P. (2018). Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. Ecancermedicalscience, 12, 824. doi:10.3332/ecancer.2018.824

Wed, 04/11/2018 - 12:00

Repurposing non-cancer drugs for breast cancer? An emerging opportunity.

presented on EBCC-11 by our colleague Sergio Crispino

Wed, 03/21/2018 - 12:00

11th European Breast Cancer Conference

21 – 23 March 2018 | Barcelona, Spain

Wed, 03/21/2018 - 12:00